Research recommendations coming out of this guidance Antibody testing: What immunomodulation strategies are effective in people with defined autoimmune epilepsy syndromes? Complex epilepsy syndromes: What antiseizure therapies (alternative or add-on) are effective in the treatment of complex epilepsy syndromes (that is, Dravet syndrome, Lennox–Gastaut syndrome, infantile spams syndrome and epilepsy with myoclonic-atonic seizures [Doose syndrome]) when first-line therapy is unsuccessful or not tolerated? Risk prediction tool for all-cause epilepsy-related death: Development of a risk prediction tool to detect all-cause mortality including sudden unexpected death in epilepsy (SUDEP) in people with epilepsy or those who have had a single seizure, and an external validation of a risk prediction tool to detect the probability of epilepsy-related death. Vagus nerve stimulation: What is the effectiveness of vagus nerve stimulation in treating epilepsy (including people with learning disabilities as a subgroup)? Psychological treatments: What is the cost effectiveness of providing tailored psychological treatments for people with epilepsy? Monitoring antiseizure medications in women and girls: What is the clinical and cost effectiveness of therapeutic drug monitoring in girls, young women and women with epilepsy? Digital health technologies: What is the clinical and cost effectiveness of digital health technologies in people with epilepsy? Antiseizure medication for repeated or cluster seizures: What antiseizure medications (monotherapy or add-on) are effective in the treatment of repeated or cluster seizures? Risk prediction tool for second seizure: Development of a risk prediction tool for second seizures in people with a single seizure, and an external validation of a risk prediction tool to detect the probability of a second seizure in people with a single seizure at baseline. Ketogenic diets: What is the short-term and long-term clinical and cost effectiveness of ketogenic diets in adults and children with drug-resistant epilepsy, and what factors affect the long-term maintenance and tolerability of ketogenic diets?
Antibody testing: What immunomodulation strategies are effective in people with defined autoimmune epilepsy syndromes?
Complex epilepsy syndromes: What antiseizure therapies (alternative or add-on) are effective in the treatment of complex epilepsy syndromes (that is, Dravet syndrome, Lennox–Gastaut syndrome, infantile spams syndrome and epilepsy with myoclonic-atonic seizures [Doose syndrome]) when first-line therapy is unsuccessful or not tolerated?
Risk prediction tool for all-cause epilepsy-related death: Development of a risk prediction tool to detect all-cause mortality including sudden unexpected death in epilepsy (SUDEP) in people with epilepsy or those who have had a single seizure, and an external validation of a risk prediction tool to detect the probability of epilepsy-related death.
Vagus nerve stimulation: What is the effectiveness of vagus nerve stimulation in treating epilepsy (including people with learning disabilities as a subgroup)?
Psychological treatments: What is the cost effectiveness of providing tailored psychological treatments for people with epilepsy?
Monitoring antiseizure medications in women and girls: What is the clinical and cost effectiveness of therapeutic drug monitoring in girls, young women and women with epilepsy?
Digital health technologies: What is the clinical and cost effectiveness of digital health technologies in people with epilepsy?
Antiseizure medication for repeated or cluster seizures: What antiseizure medications (monotherapy or add-on) are effective in the treatment of repeated or cluster seizures?
Risk prediction tool for second seizure: Development of a risk prediction tool for second seizures in people with a single seizure, and an external validation of a risk prediction tool to detect the probability of a second seizure in people with a single seizure at baseline.
Ketogenic diets: What is the short-term and long-term clinical and cost effectiveness of ketogenic diets in adults and children with drug-resistant epilepsy, and what factors affect the long-term maintenance and tolerability of ketogenic diets?